UK drug discovery startup LabGenius, which uses machine learning to find and design antibody therapies to treat cancer, has raised a £35m Series B led by the VC arm of pharma company Merck, M Ventures, with participation from Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital and Obvious Ventures. The investment brings LabGenius’s total funding to date to £58m.The company will use the capital raised to make its machine learning-driven discovery platform more comprehensive, to facil...